CLOFHIVEN INHALER BECLOMETASONE

CLOFHIVEN is indicated in the auxiliary therapy of bronchial asthma. Inhaled beclomethasone dipropionate has a glucocorticoid anti-inflammatory action on the bronchial mucosa, but at therapeutic doses it does not produce the adverse systemic effects of glucocorticosteroids. Therefore, beclomethasone dipropionate is indicated for a wide variety of patients with bronchial asthma. These patients include: Those whose asthma is getting worse and the relief provided by bronchodilators is less effective; those with severe asthma who are dependent on systemic or hormone corticosteroids (ACTH) or their synthetic equivalent. CLOFHIVEN inhalation spray is indicated only in patients who require chronic corticosteroid therapy to control symptoms of bronchial asthma. Such patients including those already receiving systemic corticosteroids and select patients, who are inadequately controlled on a nonsteroidal regimen, and whose steroid therapy has had to be stopped because of the potency of adverse effects.